dc.contributor.author | Ricco Pacheco, Natalia | |
dc.contributor.author | Flor, Amy | |
dc.contributor.author | Wolfgeher, Donald | |
dc.contributor.author | Efimova, Elena V. | |
dc.contributor.author | Ramamurthy, Aishwarya | |
dc.contributor.author | Appelbe, Oliver K. | |
dc.contributor.author | Brinkman, Jacqueline | |
dc.contributor.author | Truman, Andrew W. | |
dc.contributor.author | Spiotto, Michael T. | |
dc.contributor.author | Kron, Stephen J. | |
dc.date.accessioned | 2020-01-04T17:24:59Z | |
dc.date.available | 2020-01-04T17:24:59Z | |
dc.date.issued | 2019-06-21 | |
dc.identifier.citation | Ricco, Natalia; Flor, Amy; Wolfgeher, Don [et al.]. Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer. Molecular Oncology, vol. 13, núm. 9, p. 1927-1943. Disponible en: <https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1878-0261.12535>. Fecha de acceso: 4 ene. 2020. DOI: 10.1002/1878-0261.12535 | ca |
dc.identifier.issn | 1878-0261 | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12328/1419 | |
dc.description.abstract | Radioresistance is a major hurdle in the treatment of head and neck squamous cell carcinoma (HNSCC). Here, we report that concomitant treatment of HNSCCs with radiotherapy and mevalonate pathway inhibitors (statins) may overcome resistance. Proteomic profiling and comparison of radioresistant to radiosensitive HNSCCs revealed differential regulation of the mevalonate biosynthetic pathway. Consistent with this finding, inhibition of the mevalonate pathway by pitavastatin sensitized radioresistant SQ20B cells to ionizing radiation and reduced their clonogenic potential. Overall, this study reinforces the view that the mevalonate pathway is a promising therapeutic target in radioresistant HNSCCs. | ca |
dc.format.extent | 17 | ca |
dc.language.iso | eng | ca |
dc.publisher | Wiley | ca |
dc.relation.ispartof | Molecular Oncology | ca |
dc.relation.ispartofseries | 13;9 | |
dc.rights | © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. 1927. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | ca |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.subject.other | ADN--Anàlisi | ca |
dc.subject.other | Radiació | |
dc.subject.other | Estatines (Medicaments cardiovasculars) | |
dc.subject.other | Radioteràpia | |
dc.subject.other | ADN--Análisis | |
dc.subject.other | Radiación | |
dc.subject.other | Estatinas | |
dc.subject.other | Radioterapia | |
dc.subject.other | DNA--Analysis | |
dc.subject.other | Radiation | |
dc.subject.other | Statins (Cardiovascular agents) | |
dc.subject.other | Radiotherapy | |
dc.title | Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/acceptedVersion | ca |
dc.embargo.terms | cap | ca |
dc.subject.udc | 61 | ca |
dc.identifier.doi | https://dx.doi.org/10.1002/1878-0261.12535 | ca |